G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Laura A Volpicelli-DaleyHisham AbdelmotilibZhiyong LiuLindsay StoykaJoão Paulo Lima DaherAusten J MilnerwoodVivek K UnniWarren D HirstZhenyu YueHien T ZhaoKyle FraserRichard E KennedyAndrew B WestPublished in: The Journal of neuroscience : the official journal of the Society for Neuroscience (2017)
α-Synuclein inclusions are found in the brains of patients with many different neurodegenerative diseases. Point mutation, duplication, or triplication of the α-synuclein gene can all cause Parkinson's disease (PD). The G2019S mutation in LRRK2 is the most common known genetic cause of PD. The interaction between G2019S-LRRK2 and α-synuclein may uncover new mechanisms and targets for neuroprotection. Here, we show that expression of G2019S-LRRK2 increases α-synuclein mobility and enhances aggregation of α-synuclein in primary cultured neurons and in dopaminergic neurons of the substantia nigra pars compacta, a susceptible brain region in PD. Potent LRRK2 kinase inhibitors, which are being developed for clinical use, block the increased α-synuclein aggregation in G2019S-LRRK2-expressing neurons. These results demonstrate that α-synuclein inclusion formation in neurons can be blocked and that novel therapeutic compounds targeting this process by inhibiting LRRK2 kinase activity may slow progression of PD-associated pathology.